德国2024 - 2025年季节性流感疫苗有效性的中期估计——来自初级保健和医院哨点监测的数据

Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance.

作者信息

Erdwiens Annika, Hackmann Carolin, Wedde Marianne, Biere Barbara, Reiche Janine, Preuß Ute, Tolksdorf Kristin, Buda Silke, Dürrwald Ralf

机构信息

Department 3 Infectious Disease Epidemiology, Unit 36 Respiratory Infections, Robert Koch Institute, Berlin, Germany.

Department 1 Infectious Diseases, Unit 17 Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany.

出版信息

Influenza Other Respir Viruses. 2025 May;19(5):e70115. doi: 10.1111/irv.70115.

DOI:10.1111/irv.70115

PMID:40328669

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12055342/

Abstract

Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1-52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21-88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.

摘要

在2024年10月至2025年2月期间，甲型H1N1pdm09流感病毒最初在德国占主导地位，随后乙型维多利亚流感病毒与之共同流行。我们提供了德国2024/2025年度流感疫苗在初级保健和二级保健中的有效性（VE）的中期估计值。初级保健中针对任何流感病毒的疫苗有效性为31%（95%置信区间：1%-52%）。针对乙型流感的中期疫苗有效性较高；然而，中期估计表明，针对甲型流感的疫苗有效性要低得多，尤其是在60岁以下的成年人年龄组中。在二级保健中，针对任何流感病毒的疫苗有效性为69%（95%置信区间：21%-88%）。我们的研究结果支持在推广预防感染行为和及时进行抗病毒治疗的同时推动流感疫苗接种。